Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have earned an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $35.70.

A number of research analysts have recently weighed in on the company. TD Cowen assumed coverage on Viridian Therapeutics in a report on Monday, November 25th. They issued a “buy” rating on the stock. Royal Bank of Canada increased their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th.

Viridian Therapeutics Trading Up 1.9 %

Viridian Therapeutics stock opened at $15.43 on Thursday. The stock has a 50-day moving average of $17.16 and a two-hundred day moving average of $19.71. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics has a one year low of $11.40 and a one year high of $27.20. The stock has a market cap of $1.26 billion, a PE ratio of -3.58 and a beta of 1.05.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million. On average, research analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Voya Investment Management LLC raised its position in Viridian Therapeutics by 5.1% during the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock valued at $410,000 after acquiring an additional 1,038 shares in the last quarter. Tudor Investment Corp ET AL increased its position in shares of Viridian Therapeutics by 3.0% in the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock valued at $735,000 after buying an additional 1,106 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $26,000. Summit Investment Advisors Inc. increased its position in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after buying an additional 1,516 shares in the last quarter. Finally, AlphaQuest LLC increased its position in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after buying an additional 1,519 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.